Baxter Spins Off Drug Business To Focus On Devices, Anesthesia & Nutrition Products
This article was originally published in The Gray Sheet
Kidney dialysis and biosurgery will be two major focus points for a newly refined Baxter after it spins off its biopharmaceuticals business, as planned for mid-2015.
You may also be interested in...
Former Covidien CEO José (Joe) Almeida has been appointed CEO of Baxter as the company zeroes in on its device businesses.
JenaValve Technology names David Drachman as CEO. Ortho-Clinical Diagnostics makes executive changes following split from J&J. Baxter plans a CFO switch when it completes its biopharmaceutical company spinoff next year. More people news.
Deal builds on Baxter’s home peritoneal dialysis-focused business by adding a suite of products for hemodialysis in the clinic, including Gambro’s Artis and AK 96 systems.